NeuroSense Therapeutics

https://www.neurosense-tx.com/

NeuroSense Therapeutics (NASDAQ: NRSN) is a late-stage clinical biotechnology company focused on the discovery and development of targeted, innovative therapeutics for severe neurodegenerative diseases. Founded in 2017 by CEO Alon Ben-Noon—inspired by a chance encounter with an ALS advocate—the company operates with a profound mission to address the massive unmet medical needs of patients facing complex conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Operating from its dual headquarters in Herzliya, Israel, and Cambridge, Massachusetts, NeuroSense utilizes a unique approach to drug development: targeting multiple core pathogenic mechanisms simultaneously through synergistic, combined therapeutic strategies.

The company's flagship drug candidate is PrimeC, an advanced, proprietary fixed-dose combination of ciprofloxacin and celecoxib designed specifically to treat ALS. PrimeC tackles key drivers of the disease, including motor neuron degeneration, inflammation, and iron accumulation. The drug has been granted Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and benefits from a robust patent estate extending out to 2042. Recently, PrimeC demonstrated significant efficacy, safety, and tolerability in its PARADIGM Phase 2b clinical trial, successfully highlighting its potential to meaningfully slow disease progression and improve survival rates for those living with ALS.

Moving through late 2025 and into 2026, NeuroSense has rapidly accelerated its clinical and commercial pathways. The company recently reported transformative Phase 2b MicroRNA biomarker data further validating PrimeC as a disease-modifying treatment. Backed by positive FDA feedback regarding its pivotal Phase 3 study design, NeuroSense has also successfully completed commercial manufacturing scale-up. In parallel with its U.S. clinical strategy, the company is actively exploring expedited commercial approval pathways with Health Canada, positioning NeuroSense on the precipice of delivering a life-changing new therapy to the global ALS community.
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

Latest updates

NeuroSense Secures Brazilian Patent for PrimeC Composition, Extending IP Protection Through 2042

Event summary

  • NeuroSense Therapeutics has been granted Brazilian Patent No. BR 112024007727-6 covering its PrimeC composition.
  • The patent extends NeuroSense's intellectual property protection in Brazil through October 2042.
  • This follows prior patent grants in the U.S. and Australia.
  • PrimeC is a fixed-dose oral therapy combining ciprofloxacin and celecoxib designed to target multiple pathways in ALS and Alzheimer's disease.
  • NeuroSense is preparing for a Phase 3 pivotal clinical trial (PARAGON) for PrimeC in ALS, following positive Phase 2b PARADIGM results.

The big picture

The Brazilian patent grant represents a key step in NeuroSense's global IP strategy for PrimeC, a therapy targeting the substantial and growing market for ALS and Alzheimer's treatments. Securing patent protection in emerging markets like Brazil is increasingly important for biotech companies seeking to expand beyond established markets. The company's progress hinges on the success of the upcoming Phase 3 trial, which will determine whether PrimeC can deliver on its promise of a multi-target disease-modifying approach.

What we're watching

Regulatory Hurdles
The success of the PARAGON trial and subsequent regulatory approval in Brazil will be critical for PrimeC's commercial viability, given the stringent requirements for new therapies in the region.
Commercialization
NeuroSense's ability to secure partnerships or distribution agreements for PrimeC in Brazil will significantly impact its market penetration and revenue generation potential.
Competitive Landscape
The emergence of competing therapies targeting ALS and Alzheimer's disease could erode PrimeC's market share and necessitate further differentiation through clinical data and strategic positioning.

NeuroSense PrimeC Data Bolsters ALS Candidate, Finances Lag

Event summary

  • NeuroSense's PrimeC demonstrated a 65% reduction in ALS-related mortality risk and a >14-month median survival advantage in Phase 2b data, published in JAMA Neurology.
  • The company received FDA clearance in November 2025 to initiate the Phase 3 PARAGON trial for PrimeC in ALS.
  • Research and development expenses increased to $6.2 million in 2025, up from $5.7 million in 2024, primarily due to increased share-based compensation and salaries.
  • NeuroSense ended 2025 with approximately $0.2 million in cash.

The big picture

NeuroSense's progress with PrimeC represents a potential breakthrough in ALS treatment, a field with significant unmet need and a growing patient population. The publication in JAMA Neurology lends considerable credibility to the candidate, but the company's precarious financial position introduces substantial risk. The ability to secure funding and successfully navigate the Phase 3 trial will be crucial for realizing the potential value of PrimeC and NeuroSense's broader pipeline.

What we're watching

Execution Risk
The success of the PARAGON Phase 3 trial is critical for PrimeC's advancement and NeuroSense's valuation, and any setbacks could significantly impact investor confidence.
Regulatory Pathway
The upcoming pre-NDS meeting with Health Canada will be pivotal in determining the timeline and potential requirements for PrimeC's regulatory approval in Canada.
Financial Sustainability
NeuroSense's limited cash reserves necessitate either a financing round or a strategic partnership to fund ongoing development and the Phase 3 trial, and the ability to secure such funding will be a key determinant of its long-term viability.

NeuroSense Delays Health Canada Submission to Bolster PrimeC Data

Event summary

  • NeuroSense rescheduled its pre-New Drug Submission (pre-NDS) meeting with Health Canada to May 2026.
  • The delay is to incorporate additional clinical, biomarker, and survival data into the briefing package for PrimeC.
  • NeuroSense is pursuing the NOC/c pathway in Canada to expedite potential approval.
  • The company anticipates reporting Alzheimer's disease study results in the coming weeks.
  • PrimeC is a combination therapy of ciprofloxacin and celecoxib targeting multiple pathways in ALS and Alzheimer's disease.

The big picture

NeuroSense's decision to delay the Health Canada submission highlights the increasing scrutiny and data demands surrounding neurodegenerative disease treatments. The company's focus on a multi-mechanistic approach with PrimeC, while potentially advantageous, also introduces complexity and risk in demonstrating efficacy. The NOC/c pathway offers a faster route to market, but success hinges on a robust data package and a favorable regulatory assessment.

What we're watching

Regulatory Risk
The revised data package may not satisfy Health Canada, potentially delaying approval and impacting the NOC/c pathway timeline.
Alzheimer's Data
The upcoming Alzheimer's study results will be crucial in determining PrimeC's broader therapeutic potential and influencing investor sentiment.
Clinical Execution
Successful execution of the Phase 3 PARAGON trial in ALS will be essential to validate PrimeC's efficacy and support future regulatory submissions.

NeuroSense Presents Phase 2 Data, Advances ALS Trial Design

Event summary

  • NeuroSense will present data from its Phase 2b PARADIGM trial for PrimeC at the AD/PD™ 2026 conference in Copenhagen on March 19, 2026.
  • The presentation focuses on clinical and biomarker insights informing the design of the ongoing Phase 3 PARAGON trial for ALS.
  • The PARAGON Phase 3 trial is a multinational, randomized, double-blind, placebo-controlled study.
  • PrimeC is a combination therapy consisting of ciprofloxacin and celecoxib, designed to target multiple pathways in ALS and AD.

The big picture

NeuroSense's advancement of PrimeC represents a continued effort to address the significant unmet need in ALS treatment, a market burdened by a high disease burden and limited therapeutic options. The presentation of Phase 2 data and the ongoing Phase 3 trial underscore the company's commitment to disease-modifying therapies, but also highlight the inherent risks associated with late-stage clinical development in neurodegenerative diseases. The reliance on biomarker analysis suggests a shift towards precision medicine approaches in ALS, which could be a key differentiator for PrimeC.

What we're watching

Trial Execution
The success of the PARAGON Phase 3 trial hinges on patient enrollment and adherence to the protocol, given the disease's rapid progression and patient attrition rates.
Regulatory Path
NeuroSense's ability to secure marketing authorization will depend on the PARAGON trial results and ongoing engagement with regulatory bodies, potentially facing scrutiny given the complexity of ALS treatment.
Competitive Landscape
The emergence of other ALS therapies and biomarkers will likely intensify competition and may impact PrimeC's market share and pricing strategy.

NeuroSense ALS Trial Data Published, Paving Way for Phase 3

Event summary

  • NeuroSense's PARADIGM Phase 2b trial of PrimeC in ALS patients was published in JAMA Neurology on March 16, 2026.
  • The trial demonstrated a 7.92-point advantage in ALSFRS-R at 18 months (p=0.007) and a 64% relative reduction in ALS-related complications (p=0.02).
  • PrimeC, a combination therapy of celecoxib and ciprofloxacin, showed modulation of ALS-related microRNAs and iron-regulatory biomarkers.
  • The trial enrolled 68 participants across Italy, Canada, and Israel, with a 2:1 ratio of PrimeC to placebo during a 6-month blinded period followed by a 12-month open-label extension.
  • Findings support advancement to a confirmatory Phase 3 clinical trial, which has already received FDA clearance.

The big picture

The publication of positive Phase 2b data for PrimeC represents a significant advancement in the ALS therapeutic landscape, a field with a high unmet need and limited treatment options. While the Phase 2b trial wasn't powered for definitive efficacy, the consistent clinical and biomarker findings provide a strong foundation for Phase 3 development. The success of PrimeC could represent a paradigm shift in ALS treatment, moving beyond symptomatic management towards disease modification, but faces the typical risks associated with late-stage clinical trials and commercialization.

What we're watching

Phase 3 Execution
The success of NeuroSense hinges on the efficient and effective execution of the Phase 3 trial, given the relatively modest sample size of the Phase 2b study.
Biomarker Validation
How consistently the observed biomarker modulation translates to clinical benefit in a larger Phase 3 cohort will be critical for establishing PrimeC’s disease-modifying potential.
Competitive Landscape
The emergence of other ALS therapies will likely intensify, potentially impacting PrimeC’s market share and pricing, requiring NeuroSense to demonstrate a clear clinical advantage.

NeuroSense PrimeC Data Shows Significant Survival Benefit in ALS Trial

Event summary

  • NeuroSense's Phase 2b PARADIGM trial data for PrimeC demonstrated a 65% reduction in the risk of death (hazard ratio: 0.35; p=0.0037) in ALS patients.
  • The trial showed a median survival benefit of 14.3 months (36.3 months vs. 21.4 months; log-rank p=0.0218) for PrimeC recipients compared to placebo.
  • The data, presented by Dr. Jinsy Andrews, also indicates PrimeC regulates iron metabolism and miRNA in ALS, suggesting target engagement.
  • The PARADIGM trial involved 68 participants randomized 2:1 to PrimeC or placebo, with a subsequent open-label extension phase.

The big picture

NeuroSense's PrimeC data represents a potentially significant advancement in ALS treatment, a market with a substantial disease burden and limited therapeutic options. The observed survival benefit, coupled with the drug's mechanism of action, could accelerate its path to regulatory approval and commercialization. However, the company faces the inherent risks associated with late-stage clinical development and the competitive pressures within the neurodegenerative disease space.

What we're watching

Regulatory Pathway
The speed and success of NeuroSense's ongoing engagement with regulatory authorities will be critical in determining the timeline for potential marketing authorization of PrimeC.
Phase 3 Execution
The design and execution of the Phase 3 trial will need to replicate the survival benefits observed in PARADIGM to support approval.
Competitive Landscape
The emergence of competing ALS therapies could erode PrimeC’s potential market share and pricing power, especially given the disease's significant unmet need.

NeuroSense ALS Trial Data Shows Significant Survival Benefit

Event summary

  • NeuroSense announced long-term survival data from the PARADIGM Phase 2b ALS trial.
  • PrimeC demonstrated a 65% reduction in the risk of death (HR: 0.35, p=0.0037) compared to placebo.
  • Median survival was extended by over 14 months (36.3 months vs. 21.4 months) in the PrimeC group.
  • The trial involved 68 patients with ALS, administered PrimeC or placebo in a 2:1 ratio.

The big picture

ALS remains a devastating disease with a high unmet need, and PrimeC's survival benefit represents a potentially significant advancement. While Phase 2 data is encouraging, the high failure rate in late-stage drug development means NeuroSense faces substantial risk. The company's ability to secure funding and navigate regulatory hurdles will be crucial for realizing the potential of PrimeC and addressing the $1 billion annual disease burden.

What we're watching

Regulatory Pathway
The FDA's response to NeuroSense's data and the potential for accelerated approval pathways will be critical for PrimeC's advancement.
Pivotal Trials
Success in pivotal, late-stage trials will be necessary to validate these findings and secure market approval, given the relatively small sample size of the Phase 2b study.
Market Adoption
The willingness of physicians and patients to adopt a novel ALS treatment, particularly given the disease's aggressive progression and limited options, will influence PrimeC's commercial success.

NeuroSense Bolsters PrimeC IP Protection with Australian Patent Grant

Event summary

  • NeuroSense Therapeutics received a patent grant from the Australian Patent Office (Patent No. 2022370513) covering the composition of PrimeC.
  • The patent extends NeuroSense’s patent coverage for PrimeC through October 2042.
  • This grant follows prior patent approval in the U.S. (Patent No. 12,097,185).
  • PrimeC is Phase 3-ready for ALS, based on positive Phase 2b PARADIGM results and FDA clearance.

The big picture

NeuroSense’s aggressive IP strategy for PrimeC underscores the company’s commitment to protecting its novel combination therapy approach for neurodegenerative diseases. The extended patent life provides a degree of exclusivity crucial for recouping the significant R&D investment and attracting further funding, but also highlights the inherent risks associated with relying on patent protection in a competitive pharmaceutical landscape. The Phase 3 trial results will be the ultimate arbiter of PrimeC's value.

What we're watching

Commercialization
The success of PrimeC’s Phase 3 trials will be critical to justifying the substantial investment in IP protection and ultimately determining its commercial viability in both ALS and Alzheimer’s markets.
Patent Defense
NeuroSense will need to actively defend its patents against potential challenges, as pharmaceutical IP is frequently contested, particularly given the combination therapy approach.
Geographic Expansion
The company's strategy to secure patents in key global markets will continue, and the speed of approvals in other jurisdictions will influence PrimeC’s potential revenue streams.

NeuroSense Secures Patent for Alzheimer's Treatment, Awaits Trial Data

Event summary

  • NeuroSense has been granted U.S. Patent No. 12,527,768, covering the use of its PrimeC combination for treating Alzheimer's disease.
  • The patent extends NeuroSense's intellectual property protection through 2043.
  • The company recently completed a proof-of-concept study (RoAD) for PrimeC in Alzheimer's disease, reporting favorable safety and tolerability.
  • Clinical and biomarker data from the RoAD study are expected in Q1 2026.
  • PrimeC is a combination of ciprofloxacin and celecoxib, designed to target multiple mechanisms in Alzheimer's and ALS.

The big picture

Alzheimer's disease represents a massive, underserved market with significant unmet need for disease-modifying therapies. While existing treatments offer limited symptomatic relief, NeuroSense's PrimeC combination, targeting multiple disease mechanisms, represents a potential shift towards more effective interventions. The patent strengthens NeuroSense’s position in a competitive landscape, but the RoAD trial results will be the immediate catalyst for investor confidence.

What we're watching

Clinical Efficacy
The upcoming Q1 2026 biomarker and clinical data release from the RoAD study will be critical in assessing PrimeC’s true therapeutic potential and will likely drive near-term stock performance.
Commercialization
The long patent life (through 2043) provides NeuroSense runway, but the company's ability to successfully navigate regulatory hurdles and establish a commercialization strategy will be key to realizing the patent's value.
Pipeline Expansion
NeuroSense's stated intention to explore PrimeC's use in other neurodegenerative conditions suggests a broader pipeline strategy; the success of this approach will depend on demonstrating consistent efficacy and safety across different disease states.

NeuroSense Bolsters Alzheimer's Pipeline with Harvard Expert

Event summary

  • NeuroSense (NRSN) added Steven E. Arnold, a Harvard Medical School professor, to its Scientific Advisory Board.
  • Arnold's expertise focuses on biomarker-driven clinical development and translational neuroscience, aligning with NeuroSense's approach to both ALS and Alzheimer's programs.
  • The company recently completed a proof-of-concept Alzheimer's disease study (RoAD) demonstrating favorable safety and tolerability.
  • Clinical and biomarker data from the RoAD study is expected in Q1 2026.
  • PrimeC, NeuroSense's lead candidate, combines ciprofloxacin and celecoxib to target multiple pathways in both ALS and Alzheimer's.

The big picture

NeuroSense's move to recruit a leading Alzheimer's expert underscores the ongoing effort to develop disease-modifying therapies for a market with significant unmet need. The company's strategy of combining existing drugs to target multiple pathways represents a potentially cost-effective approach to drug development, but also carries inherent risks related to synergistic effects and regulatory approval. The RoAD study results will be a key data point for investors assessing the viability of this strategy.

What we're watching

Clinical Data
The release of RoAD clinical and biomarker data in Q1 2026 will be critical in assessing PrimeC's potential efficacy in Alzheimer's, and will likely drive near-term stock performance.
Program Expansion
How NeuroSense leverages Professor Arnold's expertise to expand its Alzheimer's disease program beyond the initial RoAD study will indicate the company's commitment to this indication.
Multi-Target Approach
The success of PrimeC's multi-target mechanism in addressing the complexity of Alzheimer's disease will determine if this approach can deliver meaningful therapeutic advances compared to existing symptomatic treatments.

NeuroSense Alzheimer's Trial Shows Favorable Safety Profile

Event summary

  • NeuroSense reported the completion of a safety analysis from its Phase 2 NST-AD-001 study of PrimeC in Alzheimer's disease.
  • The study indicated a favorable tolerability profile with no serious adverse events or unexpected safety signals.
  • Clinical and biomarker outcome data are expected to be released in Q1 2026.
  • PrimeC is a combination of ciprofloxacin and celecoxib, both FDA-approved drugs, in an extended-release oral formulation.

The big picture

Alzheimer's disease represents a significant unmet medical need with limited treatment options, driving intense research and development efforts. NeuroSense's strategy of combining existing drugs to target multiple disease mechanisms is a common approach in the neurodegenerative space, but success hinges on demonstrating both safety and efficacy. The favorable safety profile reported here is a necessary, but not sufficient, condition for PrimeC's advancement.

What we're watching

Clinical Outcomes
The release of clinical and biomarker data in Q1 2026 will be critical in determining whether PrimeC demonstrates any therapeutic efficacy beyond safety and tolerability, and will likely drive near-term stock performance.
Regulatory Pathway
The FDA's assessment of the Phase 2 data, particularly if efficacy signals emerge, will dictate the feasibility of advancing PrimeC to larger, pivotal trials and the potential for eventual market approval.
Nasdaq Listing
NeuroSense's ability to maintain its Nasdaq listing will depend on continued positive clinical data and overall financial performance, as highlighted in the forward-looking statements.
CID: 138